Taysha Gene Therapies, Inc. reports company developments as a clinical-stage biotechnology company advancing adeno-associated virus, or AAV, gene therapies for severe monogenic diseases of the central nervous system. Its lead program, TSHA-102, is an intrathecally delivered, self-complementary AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.
Recurring updates cover TSHA-102 clinical and preclinical data, FDA regulatory interactions and designations, manufacturing and comparability topics, financial results, corporate updates, and employee inducement equity grants under Nasdaq listing rules. Company communications also describe the program’s MECP2 construct design, miRARE technology, and clinical trial activity in Rett syndrome.
Taysha Gene Therapies Inc. (Nasdaq: TSHA) announced a partnership with Invitae to advance two genetic testing programs: Detect Lysosomal Storage Diseases and Behind the Seizure. These initiatives aim to enhance rapid diagnosis and patient identification for conditions like GM2 gangliosidosis and epilepsy. Eligible individuals will receive genetic testing and counseling at no cost, facilitating access to clinical trials and therapeutic interventions. The partnership is positioned to improve patient outcomes through earlier diagnoses and precision therapies, aligning with Taysha's mission to eradicate monogenic CNS diseases.
Taysha Gene Therapies (Nasdaq: TSHA) has announced the completion of its initial public offering, raising approximately $181 million. Underwriters exercised an option to purchase additional shares at $20.00 each, with the issuance closing on September 29, 2020. This offering is focused on funding AAV-based gene therapies for central nervous system diseases. Goldman Sachs, Morgan Stanley, and Jefferies were the main managers for the IPO, which was registered and declared effective by the SEC on September 23, 2020.